How to increase upstream AAV and lentiviral vector titers and ensure scalability?

by John Sotirakos | December 5, 2023

cba02ea6-c2fd-48f9-8041-46d37e15fc5c

Adeno-associated viral (AAV) vectors and lentiviral vectors are essential for delivery of genetic material into target cells for production of cell and gene therapies. As the opportunities to improve patient outcomes using these therapies rapidly expands, more efficient methods for upstream viral vector production are needed. Historic approaches for vector production relied on adherent cell cultures that could be scaled out but not up, and media formations that were not optimized and typically supplemented with fetal bovine serum. The result was limited cell growth, low viral vector productivity, and the possible introduction of adventitious agents. These methods also come up short in terms of process economics and scalability when expanding to larger patient populations.

Alternatively, purpose-built solutions enable robust suspension culture systems that deliver significant benefits for upstream viral vector production processes including the:

  • Production of significantly higher doses per batch.
  • Use of chemically defined animal component-free medium which reduces safety risks and overall process variability.
  • Ability to scale up culture vessels, not just scale out.
  • Reduction in costs and use of processes that are less labor intensive.

Explore the components of a cell suspension culture system for production of AAV and lentiviral vectors and how this approach offers a robust alternative to adherent culture systems.

Learn more today!

[molongui_author_box]

Related Posts

Starting your journey into manufacturing – choosing a cell line development provider

One of the biggest decisions which any company developing biological medicines makes is to move forward to the manufacture of their product. …

GEN Regulatory Podcast link LIVE!

The success of cell and gene therapy products in recent years to treat a host of complex diseases…

Assembling a new gene therapy company to develop the next generation of pioneering medicines

Having both recently graduated from our Masters degrees, Christina in Neuroscience from ETH Zürich and Charlotte in Chemistry…

Webinar: Developing A Scalable Upstream Bioreactor Process for Lentiviral Vector Production in Suspension

Gene therapies hold the promise to change lives. As your path to patients accelerates, how can you assure…

Scroll to Top